ADC Therapeutics SA of Lausanne, Switzerland has priced an upsized US public offering of its common shares yielding gross proceeds of $204 million to support the commercialisation of an antibody-drug conjugate (ADC) for diffuse large B cell lymphoma. The offering of six million shares was priced at $34 per share and will close on 28 September. In addition, certain existing shareholders have granted the underwriters a 30-day option to purchase up to 900,000 additional common shares.
ADC Therapeutics is listed on the New York Stock Exchange.